Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Albumin on Renal Function in Septic Shock and High-Risk AKI
2024-518475-58-00Phase 4Authorised
- Sponsor
- Fundació Parc Taulí
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of albumin (human) in septic shock and acute kidney failure (AKF) (2 arms), sponsored by Fundació Parc Taulí. Planned start Feb 2025; status: authorised.
02
Drugs
albumin (human)
03
Conditions
septic shockacute kidney failure (AKF)
Beyond the preview
Go deeper on 2024-518475-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518475-58-00.